Single-center trials have shown that urate-lowering treatment with allopurinol or febuxostat could slow the progression of chronic
23, 24 Hence, the
The present research showed that allopurinol did not significantly improve renal
The impact of allopurinol, a urate-lowering therapy, on renal function is unclear
Bethesda, MD 20894 HHS Vulnerability Disclosure Allopurinol, a xanthine oxidase inhibitor, is a urate-lowering medication that is FDA approved for managing gout, preventing tumor lysis syndrome
Aluminium hydroxide — effects of allopurinol may be reduced if taken concurrently with aluminium hydroxide
Allopurinol Zyloric, Uricto
Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular Prophylaxis of gout and of uric acid and calcium oxalate renal stones (usual maintenance in moderately severe conditions), Prophylaxis of hyperuricaemia associated with cancer chemotherapy (usual maintenance in moderately severe conditions) 300–600 mg daily in divided doses (max
In patients with decreased renal function or who have concurrent illnesses which can affect renal function, The build-up of uric acid into crystals can damage the kidneys
Methods
A possible reno-protective effect in febuxostat over allopurinol was seen
People with CKD have an increased prevalence of cardiovascular disease (CVD)
It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy
AKI development was higher in allopurinol group than febuxostat group (19
Single-center trials have shown that urate-lowering treatment with allopurinol or febuxo- The aim of this study was to evaluate the effect of allopurinol on chronic kidney disease progression
2068443